Phase II randomized trial finds microbubble-based radiosensitization enhances outcomes in hepatocellular carcinoma, indicating improved efficacy and safety compared to TARE.
Compared with treatment with only 90 Y–transarterial radioembolization (TARE), adding microbubble-based radiosensitization via ultrasound-triggered microbubble destruction to 90 Y-TARE had similar safety, provided improved treatment response, and prolonged survival in participants with hepatocellular carcinoma.
No takes yet. Share an insight, caveat, or question.
Wessner et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: